1. Witkop CJ Jr: Albinism. Clin Dermatol 7:80-91, 1989
2. Witkop CJ Jr: Inherited disorders of pigmentation. Clin Dermatol 3:70-134, 1985
3. King RA, Oetting WS: Oculocutaneous albinism. In: The Pigmentary System: Physiology and Pathophysiology, 2nd edition, edited by JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Massachusetts, Blackwell, 2006, pp. 599-612
4. Kromberg JG, Jenkins T: Prevalence of albinism in the South African negro. S Afr Med J 61:383-386, 1982
5. Spritz RA et al: Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). Am J Hum Genet 56:1320-1323, 1995
6. Keeler C: The incidence of Cuna moon-child albinos. J Hered 55:115-120, 1964
7. Oetting WS et al: Oculocutaneous Albinism Type 1: The Last 100 Years. Pigment Cell Res 16:307-311, 2003.doi:10.1034/j.1600-0749.2003.00045.x
8. Suzuki T, Tomita Y: Recent advances in genetic analyses of oculocutaneous albinism types 2 and 4. J Dermatol Sci 51:1-9, 2008
9. Wei ML: Hermansky-Pudlak syndrome: A disease of protein trafficking and organelle function. Pigment Cell Res 19:19-42, 2006. doi:10.1111/j.1600-0749.2005.00289.x
10. Dourmishev AL et al: Waardenburg syndrome. Int J Dermatol 38:656-663, 1999.doi:10.1046/j.1365-4362.1999.00750.x
11. Nayak CS, Isaacson G: Worldwide distribution of Waardenburg syndrome. Ann Otol Rhinol Laryngol 112:817-820, 2003
12. Creel D et al: Auditory brainstem anomalies in human albinos. Science 209:1253-1255, 1980
13. Lund RD: Uncrossed visual pathways of hooded and albino rats. Science 149:1506-1507, 1965
14. Gimenez E et al: A transgenic mouse model with inducible Tyrosinase gene expression using the
tetracycline (Tet-on) system allows regulated rescue of abnormal chiasmatic projections found in albinism.
Pigment Cell Res 17:363-370, 2004
15. Lavado A et al: Ectopic expression of tyrosine hydroxylase in the pigmented epithelium rescues the retinal abnormalities and visual function common in albinos in the absence of melanin. J Neurochem 96:1201-1211, 2006
16. Summers C: Albinism: Classification, clinical characteristics, and recent findings. Optom Vis Sci 86:659-662, 2009
17. Tomita Y et al: Human oculocutaneous albinism caused by single base insertion in the tyrosinase gene. Biochem Biophys Res Commun 164:990-996, 1989
18. Spritz RA et al: Detection of mutations in the tyrosinase gene in a patient with type IA oculocutaneous albinism. N Engl J Med 322:1724-1728, 1990
19. Giebel LB et al: A frequent tyrosinase gene mutation in classic, tyrosinase-negative (type IA) oculocutaneous albinism. Proc Natl Acad Sci USA 87:3255-3258, 1990
20. Hutton SM, Spritz RA: Comprehensive analysis of oculocutaneous albinism among non-hispanic caucasians shows that OCA1 is the most prevalent OCA type. J Invest Dermatol 128:2442-2450, 2008
21. King RA, Oetting WS: Molecular basis of type IA (tyrosinase negative) oculocutaneous albinism. Pigment Cell Res 5(Suppl. 2):249-253, 1992
22. Park HY et al: Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. J Biol Chem 274:16470-16478, 1999
23. Oetting WS, Fryer JP, King RA: Mutations of the human tyrosinase gene associated with tyrosinase related oculocutaneous albinism (OCA1). Hum Mutat 12:433-434, 1998
24. Tripathi RK et al: Tyrosinase gene mutations in type I (tyrosinase-deficient) oculocutaneous albinism define two clusters of missense substitutions. Am J Med Genet 43:865-871, 1992
25. Chintamaneni C et al: A single base insertion in the putative transmembrane domain of the tyrosinase gene as a cause for tyrosinase-negative oculocutaneous albinism. Proc Natl Acad Sci USA 88:5272-5276, 1991.10.1073/pnas.88.12.5272.
26. Giebel LB et al: Tyrosinase gene mutations associated with type IB (“yellow”) oculocutaneous albinism. Am J Hum Genet 48:1159-1167, 1991
27. King RA et al: Temperature-sensitive tyrosinase associated with peripheral pigmentation in oculocutaneous albinism. J Clin Invest 87:1046-1053, 1991
28. Berson JF et al: A common temperature-sensitive allelic form of human tyrosinase is retained in the endoplasmic reticulum at the nonpermissive temperature. J Biol Chem 275:12281-12289, 2000
29. Halaban R et al: Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism. Proc Natl Acad Sci USA 97:5889-5894, 2000
30. Toyofuku K et al: Oculocutaneous albinism types 1 and 3 are ER retention diseases: Mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins. Faseb J 15:2149-2161, 2001
31. Kwon BS, Halaban R, Chintamaneni C: Molecular basis of mouse Himalayan mutation. Biochem Biophys Res Commun 161:252-260, 1989
32. Lyons LA et al: Tyrosinase mutations associated with Siamese and Burmese patterns in the domestic cat (Felis catus). Anim Genet 36:119-126, 2005
33. Rinchik EM et al: A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 361:72-76, 1993
34. Woolf CM: Albinism (OCA2) in amerindians. Am J Phys Anthropol 128:118-140, 2005
35. Lee ST et al: Organization and sequence of the human P gene and identification of a new family of transport proteins. Genomics 26:354-363, 1995
36. Rosemblat S et al: Identification of a melanosomal membrane protein encoded by the pink-eyed dilution (type II oculocutaneous albinism) gene. Proc Natl Acad Sci USA 91:12071-12075, 1994
37. Lee S-T et al: Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med 330:529-534, 1994.10.1056/NEJM199402243300803
38. Durham-Pierre D et al: African origin of an intragenic deletion of the human P gene in tyrosinase positive oculocutaneous albinism. Nat Genet 7:176-179, 1994
39. Durham-Pierre D et al: Estimation of carrier frequency of a 2.7 kb deletion allele of the P gene associated with OCA2 in African-Americans. Hum Mutat 7:370-373, 1996
40. Stevens G et al: An intragenic deletion of the P gene is the common mutation causing tyrosinase-positive oculocutaneous albinism in southern African Negroids. Am J Hum Genet 56:586-591, 1995
41. Puri N et al: Type 2 oculocutaneous albinism (OCA2) in Zimbabwe and Cameroon: Distribution of the 2.7-kb deletion allele of the P gene. Hum Genet 100:651-656, 1997
42. Lund PM et al: Oculocutaneous albinism in an isolated Tonga community in Zimbabwe. J Med Genet 34:733-735, 1997
43. Stevens G, Ramsay M, Jenkins T: Oculocutaneous albinism (OCA2) in sub-Saharan Africa: Distribution of the common 2.7-kb P gene deletion mutation. Hum Genet 99:523-527, 1997
44. Kerr R et al: Identification of P gene mutations in individuals with oculocutaneous albinism in sub-Saharan Africa. Hum Mutat 15:166-172, 2000
45. Witkop CJ Jr et al: Medical and dental findings in the Brandywine isolate. Ala J Med Sci 3:382-403, 1966
46. Witkop CJ Jr et al: Tyrosinase positive oculocutaneous albinism among the Zuni and the Brandywine triracial isolate: Biochemical and clinical characteristics and fertility. Am J Phys Anthropol 36:397-405, 1972
47. Brilliant MH: The mouse p (pink-eyed dilution) and human P genes, oculocutaneous albinism type 2 (OCA2), and melanosomal pH. Pigment Cell Res 14:86-93, 2001
48. Yi Z et al: A 122.5-kilobase deletion of the P gene underlies the high prevalence of oculocutaneous albinism type 2 in the Navajo population. Am J Hum Genet 72:62-72, 2003
49. Carrasco A et al: A splice site mutation is the cause of the high prevalence of oculocutaneous albinism type 2 in the Kuna population. Pigment Cell Melanoma Res 22:645-647, 2009
50. Puri N, Gardner JM, Brilliant MH: Aberrant pH of melanosomes in pink-eyed dilution (p) mutant melanocytes. J Invest Dermatol 115:607-613, 2000
51. Brilliant M, Gardner J: Melanosomal pH, pink locus protein and their roles in melanogenesis. J Invest Dermatol 117:386-387, 2001
52. Duffy DL et al: A Three-single-nucleotide polymorphism haplotype in intron 1 of OCA2 explains most human eye-color variation. Am J Hum Genet 80:241-252, 2007
53. Azzato EM et al: Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 102:650-662, 2010
54. Staleva L, Manga P, Orlow S: Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. Mol Biol Cell 13:4206-4220, 2002
55. Kromberg JG et al: Albinism and skin cancer in Southern Africa. Clin Genet 36:43-52, 1989
56. King RA et al: Hypopigmentation in Angelman syndrome. Am J Med Genet 46:40-44, 1993
57. Wiesner GL et al: Hypopigmentation in the Prader-Willi syndrome. Am J Hum Genet 40:431-442, 1987
58. Hamabe J et al: DNA deletion and its parental origin in Angelman syndrome patients. Am J Med Genet 41:64-68, 1991
59. Hamabe J et al: Molecular study of the Prader-Willi syndrome: Deletion, RFLP, and phenotype analyses of 50 patients. Am J Med Genet 41:54-63, 1991
60. Boissy RE et al: Mutation in and lack of expression of tyrosinase-related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: A new subtype of albinism classified as “OCA3”. Am J Hum Genet 58:1145-1156, 1996
61. Manga P et al: Rufous oculocutaneous albinism in southern African Blacks is caused by mutations in the TYRP1 gene. Am J Hum Genet 61:1095-1101, 1997
62. Forshew T et al: Identification of novel TYR and TYRP1 mutations in oculocutaneous albinism. Clin Genet 68:182-184, 2005.doi:10.1111/j.1399-0004.2005.00460.x
63. Rooryck C et al: Oculocutaneous albinism with TYRP1 gene mutations in a Caucasian patient. Pigment Cell Res 19:239-242, 2006.doi:10.1111/j.1600-0749.2006.00298.x.
64. Chiang P-W et al: Synergistic interaction of the OCA2 and OCA3 genes in a family. Am J Med Genet A 146A:2427-2430, 2008
65. Kobayashi T et al: Tyrosinase stabilization by Tyrp1 (the brown locus protein). J Biol Chem 273:31801-31805, 1998
66. Newton JM et al: Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet 69:981-988, 2001
67. Inagaki K et al: Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet 74:466-471, 2004
68. Fukumachi S, Shimada A, Shima A: Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka. Nat Genet 28:381-385, 2001
69. Gunay-Aygun M, Huizing M, Gahl WA: Molecular defects that affect platelet dense granules. Semin Thromb Hemost 30:537-547, 2004
70. Huizing M, Gahl WA: Disorders of vesicles of lysosomal lineage: The Hermansky-Pudlak syndromes. Curr Mol Med 2:451-467, 2002
71. Anderson PD et al: Hermansky-Pudlak syndrome type 4 (HPS-4): Clinical and molecular characteristics. Hum Genet 113:10-17, 2003
72. Anikster Y et al: Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico. Nat Genet 28:376-380, 2001
73. Huizing M et al: Hermansky-Pudlak syndrome type 3 in Ashkenazi Jews and other non-Puerto Rican patients with hypopigmentation and platelet storage-pool deficiency. Am J Hum Genet 69:1022-1032, 2001
74. Tsilou ET et al: Milder ocular findings in Hermansky-Pudlak syndrome type 3 compared with Hermansky-Pudlak syndrome type 1. Ophthalmology 111:1599-1603, 2004
75. Gahl WA et al: Genetic Defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak Syndrome). N Engl J Med 338(18):1258-1265, 1998
76. Wei ML: Hermansky-Pudlak syndrome: A disease of protein trafficking and organelle function. Pigment Cell Res 19:19-42, 2006
77. Vincent LM et al: Hermansky-Pudlak syndrome type 1 in patients of Indian descent. Mol Genet Metab 97:227-233, 2009
78. Wei A et al: The first case report of a Chinese Hermansky-Pudlak syndrome patient with a novel mutation on HPS1 gene. J Dermatol Sci 56:130-132, 2009
79. Gahl WA et al: Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak Syndrome). N Engl J Med 338:1258-1265, 1998.10.1056/NEJM199804303381803
80. Oh J et al: Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet 14:300-306, 1996
81. Dell'Angelica
EC et al: Molecular characterization of the protein encoded by the Hermansky-Pudlak syndrome type 1 gene.
J Biol Chem 275:1300-1306, 2000
82. Chiang PW et al: The Hermansky-Pudlak syndrome 1 (HPS1) and HPS4 proteins are components of two complexes, BLOC-3 and BLOC-4, involved in the biogenesis of lysosome-related organelles. J Biol Chem 278:20332-20337, 2003
83. Martina JA, Moriyama K, Bonifacino JS: BLOC-3, a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4. J Biol Chem 278:29376-29384, 2003
84. Nazarian R, Falcon-Perez JM, Dell'Angelica
EC: Biogenesis of lysosome-related organelles complex 3 (BLOC-3): A complex containing the Hermansky-Pudlak syndrome (HPS) proteins HPS1 and HPS4.
Proc Natl Acad Sci USA 100:8770-8775, 2003
85. Richmond B et al: Melanocytes derived from patients with Hermansky-Pudlak Syndrome types 1, 2, and 3 have distinct defects in cargo trafficking. J Invest Dermatol 124:420-427, 2005
86. Boissy RE, Zhao Y, Gahl WA: Altered protein localization in melanocytes from Hermansky-Pudlak syndrome: Support for the role of the HPS gene product in intracellular trafficking. Lab Invest 78:1037-1048, 1998
87. Jedlitschky G et al: The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood 104:3603-3610, 2004
88. Dell'Angelica
EC et al: Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor.
Mol Cell 3:11-21, 1999
89. Huizing M et al: AP-3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes. Mol Biol Cell 12:2075-2085, 2001
90. Clark RH, Stinchcombe JC et al: Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 4:1111-1120, 2003
91. Di Pietro SM et al: Characterization of BLOC-2, a complex containing the Hermansky-Pudlak syndrome proteins HPS3, HPS5 and HPS6. Traffic 5(4):276-283, 2004
92. Gautam R et al: The Hermansky-pudlak syndrome 3 (Cocoa) protein is a component of the biogenesis of lysosome-related organelles complex-2 (BLOC-2). J Biol Chem 279(13):12935-12942, 2004
93. Boissy RE et al: Melanocyte-specific proteins are aberrantly trafficked in melanocytes of Hermansky-Pudlak syndrome-type 3. Am J Pathol 166:231-240, 2005
94. Huizing M et al: Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics. Annu Rev Genomics Hum Genet 9:359-386, 2008
95. Tomita Y, Suzuki T: Genetics of pigmentary disorders. Am J Med Genet 131C:75-81, 2004
96. Introne W, Boissy RE, Gahl WA: Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 68:283-303, 1999
97. Nagle DL et al: Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet 14:307-311, 1996
98. Karim MA et al: Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. Am J Med Genet 108:16-22, 2002
99. Valenzuela R, Morningstar WA: The ocular pigmentary disturbance of human Chediak-Higashi syndrome. A comparative light- and electron-microscopic study and review of the literature. Am J Clin Pathol 75:591-596, 1981
100. Zhao H et al: On the analysis of the pathophysiology of Chediak-Higashi syndrome. Defects expressed by cultured melanocytes. Lab Invest 71:25-34, 1994
101. de Beer HA, Anderson R, Findlay GH: Chediak-Higashi syndrome in a “Black” child. S Afr Med J 60:108-112, 1981
102. Trambas CM, Griffiths GM: Delivering the kiss of death. Nat Immunol 4:399-403, 2003
103. Barrat FJ et al: Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: A possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci USA 96:8645-8650, 1999
104. Waardenburg PJ: A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet 3:195-253, 1951
105. Baldwin CT et al: An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome. Nature 355:637-638, 1992
106. Tassabehji M et al: Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature 355:635-636, 1992
107. Tassabehji M Newton VE, Read AP: Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat Genet 8:251-255, 1994
108. Hughes AE et al: A gene for Waardenburg syndrome type 2 maps close to the human homologue of the microphthalmia gene at chromosome 3p12-p14.1. Nat Genet 7:509-512, 1994
109. Hoth CF et al: Mutations in the paired domain of the human PAX3 gene cause Klein-Waardenburg syndrome (WS-III) as well as Waardenburg syndrome Type I (WS-I). Am J Hum Genet 52:455-462, 1993
110. Pasteris NG et al: Discordant phenotype of two overlapping deletions involving the PAX3 gene in chromosome 2q35. Hum Mol Genet 2:953-959, 1993
111. Edery P et al: Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet 12:442-444, 1996
112. Bidaud C et al: Endothelin-3 gene mutations in isolated and syndromic Hirschsprung disease. Eur J Hum Genet 5:247-251, 1997
113. Hofstra RM et al: A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat Genet 12:445-447, 1996
114. Puffenberger EG et al: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79:1257-1266, 1994
115. Pingault V et al: SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet 18:171-173, 1998
116. Read AP, Newton VE: Waardenburg syndrome. J Med Genet 34:656-665, 1997
117. Liu XZ, Newton VE, Read AP: Waardenburg syndrome type II: Phenotypic findings and diagnostic criteria. Am J Med Genet 55:95-100, 1995
118. Potterf B, Arnheiter H, Pavan WJ: Transcription factor hierarchy in Waardenburg syndrome: Regulation of MITF expression by SOX10 and PAX3. Hum Genet 107:1-6, 2000
119. Bondurand N et al: Interaction among SOX10. PAX3, and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet 9:1907-1917, 2000
120. Helms JA, Schneider RA: Cranial skeletal biology. Nature 423:326-331, 2003
121. Merchant SN et al: Otopathology in a case of type I Waardenburg's syndrome. Ann Otol Rhinol Laryngol 110:875-882, 2001
122. Takasaki K, Balaban CD, Sando I: Histopathologic findings of the inner ears with Alport, Usher and Waardenburg syndromes. Adv Otorhinolaryngol 56:218-232, 2000
123. Tassabehji M et al: The mutational spectrum in Waardenburg syndrome. Hum Mol Genet 4:2131-2137, 1995
124. Sanchez-Martin M et al: SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet 11:3231-3236, 2002
125. Bondurand N et al: Deletions at the SOX10 Gene Locus Cause Waardenburg Syndrome Types 2 and 4. Am J Hum Genet 81:1169-1185, 2007
126. Hemesath TJ et al: microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8:2770-2780, 1994
127. Pingault V et al: Review and update of mutations causing waardenburg syndrome. Hum Mutat 31:391-406, 2010
128. Maroto M et al: Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89:139-148, 1997
129. Verheiji JBGM, Hofstra RMW. EDNRB, EDN3, and SOX10 and the Shah-Waardenburg syndrome. In: Inborn Errors of Development: The Molecular Basis of Clinical Disorders of Morphogenesis, edited by CJ Epstein, RP Erickson, A Wynshaw-Boris. New York, Oxford University Press, 2004, pp. 440-446
130. Tietz W: A syndrome of deaf-mutism associated with albinism showing dominant autosomal inheritance. Am J Hum Genet 15:259-264, 1963
131. Amiel J et al: Mutation of the MITF gene in albinism-deafness syndrome (Tietz syndrome). Clin Dysmorphol 7:17-20, 1998
132. Izumi K et al: Tietz syndrome: Unique phenotype specific to mutations of MITF nuclear localization signal. Clin Genet 74:93-95, 2008
133. Hodgkinson CA et al: Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74:395-404, 1993
134. Hornyak TJ et al: Transcription factors in melanocyte development: Distinct roles for Pax-3 and Mitf. Mech Dev 101:47-59, 2001
135. Smith SD et al: Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. J Med Genet 37:446-448, 2000
136. Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 38:365-411, 2004
137. Schwarzbraun T et al: A new 3p interstitial deletion including the entire MITF gene causes a variation of Tietz/Waardenburg type IIA syndromes. Am J Med Genet A 143A:619-624, 2007
138. Giebel LB, Spritz RA: Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci US A 88:8696-8699, 1991
139. Hemesath TJ et al: MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391:298-301, 1998
140. Spritz RA, Beighton P: Piebaldism with deafness: Molecular evidence for an expanded syndrome. Am J Med Genet 75:101-103, 1998
141. Miyamura Y et al: Mutations of the RNA-specific
adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria.
Am J Hum Genet 73:693-699, 2003
142. Murata I et al: Mutation analyses of patients with dyschromatosis symmetrica hereditaria: Five novel mutations of the ADAR1 gene. J Dermatol Sci 58(3):218-220, 2010
143. Filipovich AH: Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol 6:410-415, 2006
144. Gupta S, Kumar B: Epidermal grafting in vitiligo: Influence of age, site of lesion, and type of disease on outcome. J Am Acad Dermatol 49:99-104, 2003
145. Grimes PE: New insights and new therapies in vitiligo. JAMA 293:730-735, 2005.10.1001/jama.293.6.730
146. van Geel N et al: Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol 140:1203-1208, 2004.10.1001/archderm.140.10.1203
147. Cullen RD et al: Cochlear implants in Waardenburg syndrome. Laryngoscope 116:1273-1275, 2006
148. King RA et al: Albinism in Nigeria with delineation of new recessive oculocutaneous type. Clin Genet 17:259-70, 1980.
149. King RA. Albinism. In: The Pigmentary System: Physiology and Pathophysiology, 1st edition, edited by JJ Nordlund, RE Boissy, VJ Hearing, RA King, J-P Ortonne. New York, Oxford University Press, 1998, pp. 553-574
150. Saitoh S et al: Oculocutaneous albinism type 2 with a P gene missense mutation in a patient with Angelman syndrome. J Med Genet 37:392-394, 2000
151. Bahadoran P, Ortonne J-P: Albinoid Disorders. In: The Pigmentary System: Physiology and Pathophysiology, 2nd edition, edited by JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Blackwell Publishing, 2006, pp. 613-621
152. Boissy RE et al: Human tyrosinase related protein-1 (TRP-1) does not function as a DHICA oxidase activity in contrast to murine TRP-1. Exp Dermatol 7:198-204, 1998
153. Kobayashi T et al: Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. Embo J 13:5818-5825, 1994
154. Huizing M et al: Nonsense mutations in ADTB3A cause complete deficiency of the β3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr Res 51(2):150-158, 2002
155. Jung J et al: Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood 108(1):362-369, 2006
156. Wenham M et al: Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica 95:333-337, 2010
157. Huizing M et al: Cellular, molecular and clinical characterization of patients with Hermansky-Pudlak syndrome type 5. Traffic 5(9):711-722, 2004
158. Zhang Q et al: Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet 33:145-153, 2003
159. Korswagen L-A et al: A novel mutation in a Turkish patient with Hermansky–Pudlak syndrome type 5. Eur J Haematol 80:356-360, 2008
160. Schreyer-Shafir N et al: A new genetic isolate with a unique phenotype of syndromic oculocutaneous albinism: Clinical, molecular, and cellular characteristics. Hum Mutat 27:1158, 2006
161. Li W et al: Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 35:84-89, 2003
162. Morgan NV et al: A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet 78:160-166, 2006
163. Huizing M et al: Cellular, molecular and clinical characterization of patients with Hermansky-Pudlak syndrome type 5. Traffic 5:711-722, 2004, doi:10.1111/j.1600-0854.2004.00208.x
164. Zhang Q et al: Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. 33:145-153, 2003
165. Li W et al: Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). 35:84-89, 2003
166. Benson MA et al: Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. 24232-24241, 2001
167. Sadoulet-Puccio HM, Rajala M, Kunkel LM: Dystrobrevin and dystrophin: An interaction through coiled-coil motifs. 12413-12418, 1997
168. Nazarian R et al: Reinvestigation of the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related organelles complex-1) as a dystrobrevin-binding protein. Biocheml J 395:587-598, 2006
169. Gwynn B et al: Reduced pigmentation (rp), a mouse model of Hermansky-Pudlak syndrome, encodes a novel component of the BLOC-1 complex. Blood 104:3181-3189, 2004
170. Starcevic M, Dell'Angelica
EC: Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1).
J Biol Chem 279:28393-283401, 2004
171. Reed WB et al: Hereditary syndromes with auditory and dermatological manifestations. Arch Dermatol 95:456-461, 1967
172. Reed WB et al: Pigmentary disorders in association with congenital deafness. Arch Dermatol 95:176-186, 1967
173. Spritz RA: Genetic hypomelanoses: Disorders characterized by congenital white spotting-piebaldism, waardenburg syndrome, and related genetic disorders of melanocyte development-clinical aspects. In: The Pigmentary System: Physiology and Pathophysiology. 2nd edition, edited by, JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Blackwell Publishing, 2006, pp. 541-550
174. Cross HE, McKusick
VA, Breen W: A new oculocerebral syndrome with hypopigmentation.
J Pediatr 70:398-406, 1967
175. Bolognia JL: Oculocerebral syndrome with hypopigmentation. In: The Pigmentary System: Physiology and Pathophysiology. 2nd edition, JJ Nordlund, RE Boissy, VJ Hearing, RA King, WS Oetting, J-P Ortonne. Malden, Blackwell Publishing, 2006, pp. 626-630